ImClone Systems and Bristol-Myers Squibb announced the results of several clinical studies of ERBITUX, an IgG1 monoclonal antibody, presented at the American Society of Clinical Oncology (ASCO) 41st Annual Meeting.
Corgentech and Bristol-Myers Squibb Announce E2F Decoy Trial Results
Corgentech, and Bristol-Myers Squibb Company announced top-line results from PREVENT IV, a Phase 3 clinical trial evaluating the use of edifoligide (E2F Decoy).